In accordance with the National Institutes of Health (NIH) Guidelines, the National Cancer Institute-Frederick
(NCI-F) has established an Institutional Biosafety Committee (IBC) . The committee represents the interests
of the surrounding community with respect to public health and protection of the environment, animal
containment principles and biological safety.
The IBC is responsible for reviewing projects that involve, but are not limited to: rDNA/RNA; RNAi (shRNA/siRNA);
Pathogens; Oncogenes; Biological Toxins; Human Materials; Other potentially infectious material (OPIM);
Transgenic or Knock-Out/In Animals; Synthetic Biology; Nanotechnology; and Dual Use Materials.
To ensure adequate and timely review, the IBC has implemented registration submission deadlines (see
There will be no exceptions to this requirement.
All meetings will be held in Building 549 Executive Board Room from 12:00 to 3:00.
Synthetic Nucleic Acid Molecules – changes to NIH Guidelines
Investigator Responsibilities under NIH Guidelines
NIH Dual Use Research
Biosecurity News in Brief
Strain database: To determine if a particular mouse strain is registered with the NCI-Frederick IBC,
please contact NCI-Frederick